ARS PHARMACEUTICALS INC (SPRY) — insider trading
Health Care · NASDAQ
ARS PHARMACEUTICALS INC (SPRY) has 16 reported SEC Form 4 insider transactions in our data, including 2 open-market sales among the most recent 16 (latest 2026-10-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Casale Donn | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 1,036,923 | — | $0 | Form 4 |
| 2026-09-01 | Smith Margaret Ekins | Officer (Chief Commercial Officer) | Grant / award / vesting (derivative) | 1,001,738 | — | $0 | Form 4 |
| 2026-07-01 | Casale Donn | Officer (President) | Grant / award / vesting (derivative) | 898,456 | — | $0 | Form 4 |
| 2026-06-24 | Shawver Laura | Director | Grant / award / vesting (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-06-24 | SCHNEIDER PHILLIP M | Director | Grant / award / vesting (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-06-24 | SAUNDERS BRENT L | Director | Grant / award / vesting (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-06-24 | Thompson Peter A. | Director | Grant / award / vesting (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-06-24 | Islam Saqib | Director | Grant / award / vesting (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-06-24 | Kelly Michael | Director | Grant / award / vesting (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-06-24 | Shah Pratik | Director | Grant / award / vesting (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-06-24 | Dadoo Rajeev | Director | Grant / award / vesting (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-06-24 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Grant / award / vesting (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-06-12 | Fitzpatrick Alexander A | Officer (Chief Legal Officer) | Open-market sale | 3,355 | $10.00 | $33.5K | Form 4 |
| 2026-06-12 | Karas Eric | Officer (Chief Commercial Officer) | Option exercise / conversion (derivative) | 25,000 | — | $0 | Form 4 |
| 2026-06-12 | Karas Eric | Officer (Chief Commercial Officer) | Open-market sale | 25,000 | $10.00 | $250.0K | Form 4 |
| 2026-06-12 | Karas Eric | Officer (Chief Commercial Officer) | Option exercise / conversion | 25,000 | $1.50 | $37.5K | Form 4 |
Ask the chat about SPRY's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ARS PHARMACEUTICALS INC (SPRY).
Last updated 2026-10-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.